In HFmrEF or HFrEF, digitalis glycosides reduce a composite of CV death or worsening HF event vs. placebo at a median 36 to 37 mo

The authors investigate whether digitalis glycosides can reduce the risk of cardiovascular death or worsening heart failure events in patients with heart failure with mid-range or reduced ejection fraction (HFmrEF or HFrEF). Their findings indicate that treatment with digitalis glycosides is associated with a significant reduction in this composite outcome compared to placebo over a median follow-up period of 36 to 37 months.